The aim of this study was to evaluate the possibility of poly (D, L-lactide-co-glycolide) nanoparticle (NPs) as a gene vector for functional plasmid DNA (pDNA) and to investigate its inhibitory efficacy on experimental choroidal neovascularization (CNV). We developed intravitreal administered, hypoxia-inducible factor 1a (HIF-1a) short hairpin RNA and green fluorescent protein (GFP) co-expressed pDNA-loaded NPs (pshHIF-1a NPs). CNV was induced by laser photocoagulation in 112 rats. The rats were then randomly assigned to be injected intravitreally with phosphate-buffered saline (PBS), blank NPs, naked pDNA, control pDNA NPs and pshHIF-1a NPs, respectively, and non-injection group was set as the control. Immunofluorescence staining, fluorescein fundus angiography and histologic analysis were performed to evaluate the inhibitory efficacy on CNV. The results showed that the expression of GFP preferentially localized in the retinal pigment epithelium cell layer and lasted for 4 weeks. The fluorescein leakage areas of CNV were significantly larger in the PBS, blank NPs, control pDNA NPs, non-injection group and naked pDNA group than in pshHIF-1a NPs group (Po0.01). The mean thickness of the CNV lesions in the intravitreally pshHIF1a NPs-treated group was significantly smaller than other groups (Po0.01). No signs of functional or ultrastructural destruction in retina were detected. Therefore, pshHIF-1a NPs may act as a novel therapeutic option to transfer specific pDNA and inhibit the formation of experimental CNV.
Introduction
Age-related macular degeneration is the major cause of visual loss in patients older than 50 years in developed countries, and choroidal neovascularization (CNV) is responsible for the majority of severe visual loss in agerelated macular degeneration.
1 Present therapies, such as thermal laser or photodynamic therapy, however, have significant shortcomings such as full-thickness retinal damage, central visual loss, limited indications and high recurrence rates after these treatments. 2, 3 As the pathogenesis of CNV is better understood, recent studies have agreed that this clinical course is characterized by a stereotypical tissue repair response at the cellular level, 4 including fibrin deposition with provisional matrix formation, inflammation, neovascularization, 5 extracellular matrix deposition and remodeling (disciform scar formation). 6 Pivotal in the neovascular response is the production of vascular endothelial growth factor (VEGF). 7 It is suggested that anti-angiogenesis therapy may be beneficial in the treatment of CNV. Several novel therapies for CNV have emerged based on antagonism of VEGF or the VEGF receptor, 8, 9 such as intravitreal administration of bevacizumab (Avastin), ranibizumab (Lucentis) and pegaptanib (Macugen). 10 However, a potential drawback of these therapies is that there has been some evidence showing that suppressed expression of VEGF alone is not sufficient to inhibit CNV. [11] [12] [13] The initiation of a submacular wound-healing response may require a hypoxic stimulus, which in turn leads to the production of hypoxia-inducible factor-1(HIF-1), a transcription factor that functions as a master regulator of oxygen homeostasis.
14 Clinical studies have shown that the age-related changes in Bruch's membrane and the dropout of choriocapillaris cause impaired diffusion of oxygen. 15, 16 Outer retina hypoxia 17 and the resulting transcriptional activation of the HIF-1 [18] [19] [20] may become an important driving force of CNV formation by stimulating VEGF overexpression, 21, 22 in addition to the effects of increased oxidative stress and low-grade inflammation. Recently, it has also been shown that CNV membranes are positive for HIF-1 expression, and this expression tends to be localized to the retinal pigment epithelium (RPE) cells. 23 , 24 As a 'master switch' for mammalian circulation in response to low oxygen tension, HIF-1 regulates the transcription of many proangiogenic growth factors, including VEGF, erythropoietin and platelet-derived growth factor. 25, 26 Knocking down of HIF-1a gene results in the down regulation of VEGF. 27 Moreover, RPE cells senescence and hypoxia may decrease expression of angiogenesis inhibitors such as pigmentepithelium-derived factor (PEDF), further shifting the balance to a pro-angiogenic state in the aging eye. Thus, much attention has been drawn to this master modulator, because it may not only downregulate the VEGF expression, but may also adjust some other uncertain factors to achieve a synergistic effect.
The recent discovery of RNA interference (RNAi), a natural process through which the expression of a targeted gene can be knocked down with high specificity and selectivity, presents an invaluable tool for gene therapy. Target-specific RNAi agents (including siRNA, plasmid-based short hairpin RNA (shRNA) and endogenous hairpin micro-RNA) have the potential to selectively knock down key abnormally over-or constitutively expressed molecular targets. Recently, our work showed that VEGF expression could be inhibited by targeting HIF-1a with siRNA in human RPE cells. 28 Using siRNA directed against VEGF or VEGF receptors in CNV animal models have also showed promising results. [29] [30] [31] Clinical trials involving RNAi targeting VEGF or its receptor through intravitreal injection delivery are currently underway. 32 However, generating sustained expression of the transgene remains a vexing problem. Exogenous genetic materials are degraded quickly in the target cells, and thus can only transiently inhibit the angiogenesis process, which leads to the regrowth of vessels after the administration of these antiangiogenesis agents to patients. 33 To achieve efficient long-term gene expression or pharmacodynamic action in the eye, intravitreal injection must be administered repeatedly to maintain the drug concentrations within a therapeutic range for a long period of time, which sometimes causes certain ocular complications, such as vitreous hemorrhage, retinal detachment or endophthalmitis. 32 Therefore, the application of drug-delivery systems to facilitate therapeutic efficacy and to minimize side effects may be of primary consideration in our study.
An ideal controlled-release formulation should release the entrapped drugs in a continuous manner over a desired time period. 34 Biodegradable, biocompatible microspheres or nanoparticles (NPs) formulated from poly (D, L-lactide-co-glycolide) (PLGA) or poly (D, Llactide) have been extensively investigated for various drug-delivery applications. They are hydrolyzed and metabolized without direct toxic reactions to living tissues. 35 By changing physicochemical properties, such as molecular weight, hydrophilicity and the ratio of lactide to glycolide, 34, 36 the degradation rate of PLGA polymer enables the delivery of encapsulated drug to be modulated in a slow and extended intracellular release manner. Besides, antigens or DNA fragments encapsulated in PLGA matrix can be protected from endonuclease activity. 37, 38 Biodegradation and ocular tissue reaction to microspheres or NPs of poly (D, L-lactide) or PLGA have been studied earlier in vitro 39, 40 and in vivo. [41] [42] [43] [44] In this study, we showed the inhibitory efficiency of shRNA-expressing plasmid DNA (pDNA) targeting HIF1a (pshHIF-1a) on laser-induced CNV in rats, and further evaluated the therapeutic potential of PLGA NPs as a non-viral vector for pshHIF-1a gene transfection to the posterior segment of eyes.
Results

Characteristics of NPs
Average size of the pDNA-loaded NPs was 303.7±38.5 nm (Figure 1a ) and zeta potential was À8.91 ± 3.2 mV as measured by laser light scattering. The encapsulation efficiency and loading percent was 60.2 and 1.06%, respectively. The in vitro release behavior of pDNA-loaded NPs is depicted in the cumulative percentage release. The results showed that about 77% of total encapsulated pDNA was released within 10 days followed by a constant and sustained release for 4 weeks (Figure 1b) . NPs appeared to have a spherical shape and smooth surface as determined by transmission electron microscopy (TEM) (Figure 2 ).
In vivo distribution of pDNA-loaded NPs and their influence on the expression of HIF-1a
Immunofluorescence staining observation for green fluorescent protein (GFP) was carried out on days 3, 7, 14 and 28 after intravitreal administration. The confocal images showed that gene expression of GFP in control pDNA NPs-and pshHIF-1a NPs-injection eyes were detected within the retina and chorioid as early as 3 days after intraocular injection (Figure 3a) . On days 7, some cells expressing GFP were observed in the inner retinal layers, but most of the expression was localized preferentially within the RPE layer (Figure 3b) , and the protein expression remained apparent in RPE cells until pDNA-loaded nanoparticles inhibit CNV C Zhang et al days 28. The fluorescence was clearly located within RPE cytoplasm. These GFP-expressing cells ( Figure 3c ) were also found in and around CNV lesions 3 days after intraocular injection. Fluorescence for naked pDNAinjection eyes showed a short-term expression of GFP and could not be detected on day 7. Controls injected either with blank NPs or phosphate-buffered saline (PBS) showed no fluorescence at any time point (data not shown).
By immunofluorescence staining, expression of HIF-1a was observed increased in CNV lesions 3 days after laser photocoagulation (Figures 3d and f) , suggesting that there was strong upregulation of HIF-1a expression participating in CNV. The statistical insignificance (P40.05) between naked pDNA group and pshHIF-1a NPs group at day 3 indicates that the pDNA released from the NPs might be as effective as from the naked pDNA in silencing HIF-1a expression at this early phase(under the equal content of pDNA per eye). However, the expressions of HIF-1a observed in the CNV specimens of the pshHIF-1a NPs and naked pDNA-treated groups were diminished significantly compared with other groups (Figure 4 , Po0.01), suggesting that the sequence in this study (5 0 -CCAGTTGAAT CTTCAGATA-3 0 ) was functional to silence HIF-1a expression.
Inhibitory effects of pshHIF-1a NPs on the severity of CNV On day 14 after laser induction, laser-induced photocoagulation reproducibly resulted in the development of CNV, as demonstrated by fluorescein fundus angiography ( Figure 5A ). Semiquantitative analyses revealed that though PBS, blank NPs, control pDNA NPs and noninjection groups showed moderate-to-severe fluorescein leakage in CNV, the rats treated with pshHIF-1a NPs showed a statistically significant decreased fluorescein leakage in CNV membranes ( Figure 5C , Po0.01).
Histopathology revealed similar morphologic features of CNV in each group at day 14, in terms of vascular channels, fibrous stroma and macrophage infiltration at the sub-RPE and the subretinal space with ruptured Bruch membrane ( Figure 5B) Figure 5D ).
Toxicity of pshHIF-1a NPs to retina
No significant difference was found among the groups of amplitudes (or implicit times) on day 0 (P40.10). At day 7 post injection, a significant decreased amplitudes and a prolonged implicit times of a- ( TEM showed slight derangement of microtubule and microfilament in retina nerve fiber layer and the vacuolization of mitochondria was observed in pshHIF1a NPs-injected eyes at day 14 ( Figure 7B ). Some of the NPs, which were not round or elliptic in appearance, were found in the cytoplasm of ganglionic cells and around the nucleus, suggesting that they could be uptaken by retinal cells and were partial degraded. PBS group also showed signs of ultrastructure changes in the ganglionic cells and nerve fiber layer ( Figure 7A ). At day 28, no signs of apparent ultrastructure destruction in the ganglionic cells and outer segment membrane disc were detected in eyes treated with PBS-injection, except for the retinal nerve fiber layer with slight vacuolization of mitochondria ( Figure 7C ). Most of the mitochondria, rough endoplasmic reticulum, Golgi's complex in the ganglionic layer and the mitochondria, microtubule and microfilament in the nerve fiber layer were recovered with only a small amount of similar changes observed in pshHIF-1a NPs-injectied group ( Figure 7D ).
Discussion
CNV is a complex biological process that requires the precise coordination among various angiogenic factors. There is mounting evidence that VEGF has an important function in CNV pathogenesis; [45] [46] [47] however, the stimuli pDNA-loaded nanoparticles inhibit CNV C Zhang et al for excessive VEGF production in CNV in patients or animal models are complex. Grunwald et al. 48, 49 have reported that the choroidal circulation was more decreased as the severity of age-related macular degeneration features associated with a risk for the development of CNV was increased, suggesting an important role of ischemia and hypoxia in the clinical CNV formation. On the other hand, it was thought that CNV just occurs as a part of granulation tissue formation in inflammatory response to laser injury in animal models in earlier research. 50 In spite of similarities with CNV in human age-related macular degeneration, the laser model may not be appropriate for studies of mechanisms of initiation of CNV as there is extensive damage to the retinal issue and Bruch's membrane with the laser treatment. However, Vinores et al. 51 have shown that the hypoxia response element of the VEGF promoter is critical for the development of CNV after laser-induced rupture of Bruch's membrane. This may mean that laserinduced closure of choroidal vessels causes ischemia of pDNA-loaded nanoparticles inhibit CNV C Zhang et al the outer retina resulting in VEGF upregulation, which combined with the disruption of Bruch's membrane causes CNV. Moreover, their findings showed that CNV that results from laser photocoagulation is dependent on direct induction of VEGF by HIF-1a through the hypoxia response element. Thus, hypoxia may have a central role in the development of submacular wound healing, which in turn leads to the production of HIF-1, itself the key trigger for VEGF production and the subsequent development of the neovascular component of this submacular tissue repair. 52 HIF-1 regulates many angiogenic factors such as VEGF, VEGFR-1, erythropoietin, inductible nitric oxide synthase, endothelin-1 and plateletderived growth factor-B, which have important and diverse roles in different stages of angiogenesis. 28, 53 Earlier studies have indicated that disruption of the binding between HIF-1 and proangiogenic promoters may selectively diminish the activation of the HIF-1-driven target genes. 54 Therefore, inhibition of HIF-1a could directly or indirectly regulate the expression of these angiogenic factors, especially VEGF, thus leading to the suppression of CNV.
The technology of RNAi is an intriguing and powerful method of gene downregulation, which has been widely used to study gene function and target discovery. 29, 55 siRNA can degrade mRNA, which has a complementary sequence to the siRNA by the RNAi mechanism. [56] [57] [58] In addition to siRNA, DNA vectors that transcribe siRNA or shRNA are also available to induce RNAi. [59] [60] [61] Nonviral vector-based approach using pDNA is expected to be a safer method to induce RNAi compared with any approaches using viral vectors, 62, 63 and the vector-based shRNA have evolved as an extremely powerful and the most popular gene-silencing reagent currently. shRNA are more efficient than siRNA on the induction of gene silencing and can be continuously synthesized by the 
non-injection, (e) naked pDNA and (f) pshHIF-1a NPs-treated eyes 3 days after laser photocoagulation, (g) negative control (incubated without the primary antibody), (h) negative control (incubated with mouse IgG2b isotype control). (B) HIF-1a immunofluorescence staining of serial cross sections of the eye cups of rats showed that on day 3, strong fluorescence was seen in red in the CNV lesions of the PBS, blank NPs, control pDNA NPs and non-injection eye compared with minimal staining in the naked pDNA and pshHIF-1a NPs-treated eyes (*Po0.01). There was no significant difference between naked pDNA and pshHIF-1a NPs-treated eyes (P40.05). The expression of HIF-1a in the inner layer of retina might be caused by the increased intraocular tension after intravitreal injection (bar: 50 mm).
pDNA-loaded nanoparticles inhibit CNV C Zhang et al pDNA-loaded nanoparticles inhibit CNV C Zhang et al host cell, therefore, its effect should be much more durable. Concentrations of shRNA necessary for effective knockdown are usually less than of siRNA (five copies of shRNA integrated in the host genome is sufficient to provide continual gene knockdown effect). 64, 65 Besides, chemically synthesized siRNA is easier to modify through chemistry; however, bulk manufacturing of complex structures such as indicator-modified siRNA is more expensive than shRNA.
To further confirm pshHIF-1a can silence the HIF-1a gene and inhibit the development of CNV in vivo, we designed shRNA-expressing pDNA targeting against rat HIF-1a gene and found it could dramatically decrease HIF-1a expression. Immunofluorescence staining showed that the expression of HIF-1a observed in the CNV specimens from the intravitreally pshHIF-1a NPs group was apparently diminished compared with PBS-injection group or non-injection group at day 3, suggesting that pshHIF-1a transfection was functional to silence HIF-1a expression. However, there was no significance difference of HIF-1a expression between naked pDNAtreated eyes and pshHIF-1a NPs-treated eyes, suggesting that the interference efficiency of pDNA released from PLGA matrix was attenuated at the first 3 days compared with that of naked pDNA. Besides, fluorescein fundus angiography illustrated that a single intravitreal injection of pshHIF-1a NPs could attenuate vascular leakage, which was confirmed by histologic analysis of CNV thickness. We therefore concluded that pshHIF-1a could inhibit CNV growth in laser-induced rat model. Nevertheless, further studies are required to elucidate the inhibition efficacy of pshHIF-1a NPs on HIF-1a expression, by measuring the actual HIF-1a mRNA transcriptional activity and protein expression using real-time PCR and western bolt in the future.
It is interesting to note that a number of anti-VEGF therapies need repeated injections, indicating that the underlying hypoxic signal may still be present. As Figure 6 To assess retina function, f-ERG analyses of a-and b-waves were performed in rats (n ¼ 5) 7 and 28 days after intravitreal injection, and were compared with uninjected controls (baseline). When the Levene's test was rejected at the 0.1 level, a significant decrease in amplitude and a prolonged implicit time of a-and b-waves from baseline were observed in all injected eyes 7 days post injection (*Po0.05) as an immediate consequence of the injection procedure, whereas there was no significant difference in amplitudes or in implicit times among any of the intravitreal injected groups (P40.05). At day 28 post injection, no significant difference in a-and b-wave amplitudes or implicit times was observed between baseline and intravitreal injected groups (P40.05), suggesting the lack of toxicity associated with NPs or pDNA in retina. Significance was determined with Dunnett-t or SNK-q test.
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CNV occurs over time in dynamic stages of initiation, progress, involution or recurrence in human, this phenomenon is not entirely unexpected because just as in neoplastic states, which can also be characterized by hypoxia, anti-angiogenic approaches may be counterproductive in the long-term because they will continue to promote hypoxia and therefore HIF-1 expression. 13 Over the past few years, in vivo gene transfer efficiency has increased significantly. However, as the gene-silencing effect of siRNA and shRNA-expressing pDNA is transient, attention should be paid to the duration of the RNAi effect. Clinically, long-term delivery of biologically active molecules to the neuroretina and/or to the RPE is also problematic. To achieve the long-term pDNA-loaded nanoparticles inhibit CNV C Zhang et al gene expression or pharmacodynamic action in the eye, intravitreal injection has to be administered repeatedly to maintain the drug concentrations within a therapeutic range for a long period of time. Bacterial endophthalmitis is an expected and dreaded complication of any intravitreal injection. According to Marina's project, in which repeated intravitreal injections of bevacizumab were conducted in patients over 12 months, 66 seven cases (0.16%) of bacterial endophthalmitis were observed, and six of the seven eyes lost vision despite the treatment. The duration of gene-silencing effect by RNAi is determined by various factors, such as the stability of pDNA or shRNA and the proliferation rate of target cells. 67, 68 Therefore, the efficacy of an RNAi therapeutic is limited by the quantity of the oligomer that effectively enters the target cells. In the clinical setting this is primarily dependent on the method of delivery. If cell entry is mediated by endocytosis, the delivery vehicle must negotiate endosomal/lysosomal escape and, in the case of shRNA, the payload must penetrate the nuclear membrane as well. As RNAi effectors are readily degraded and their effective concentration in the cells decreases with cell division, the expression level of the target gene will return to normal. Nevertheless, there are few reports describing the duration of the gene-silencing effect on the endogenous target gene, therefore the mechanism(s) underlying this requires further studies.
Sustained drug release systems that may overcome the progressive nature of CNV, such as microimplants and microspheres and NPs, have been used to control drugrelease rates and to target drug release to specific sites in the body, so as to not only optimize therapeutic response, but also minimize toxic side effects, eliminate the inconvenience of repeated injections, Therefore, we used a notable vehicle to attempt the long-term or permanent regression of CNV. PLGA has a number of advantages over other polymers, including biodegradability, biocompatibility, and was granted the approval for human use by the Food and Drug Administration (FDA). Our present studies observed a transient GFP expression after naked pDNA gene transfer to the eye, however, GFP expression derived from the PLGA NPs was delayed by the slow release of pDNA from the matrix of PLGA polymers, which decreased the degree of the degeneration rate. No deleterious effects of pshHIF-1a NPs were found on the function of photoreceptors or their associated neurons, and no apparent signs of ultrastructural destruction in retina were detected by TEM, which is consistent with ERG. After their uptake, the NPs escape the early endo-lysosomal formation and enter the cytosolic compartment by a mechanism of surface charge reversal. 38, 69 The encapsulation of pDNA within microspheres or NPs has also been shown to preserve their in vivo functional integrity when the contact time with lysosomal enzymes is shortened. 37, 70, 71 Prior research that followed the kinetics of tissue and cellular localization of NPs loaded with either Rh-6G or Nile red also showed that the injected NPs reach the retina rapidly, homing in on the RPE cells where they were still observed 4 months after the injection; encapsulated Rh-6G dye diffused slowly from the NPs and uniformly stained the retinal layers. 72 RPE cells, as main constituents in CNV, are known to quickly respond and adapt to environmental stresses such as ischemia and metabolic changes by expressing a number of various genes, 73 and have a major role in CNV because of their essential function in neural retina homeostasis. In the early stages of CNV development, RPE promotes CNV through releasing many angiogenic-related factors, including HIF-1a. 74 Therefore, RPE cells are especially of our interest as they are a potential target for HIF-1a-directed siRNA transfer, which aims at arresting or reversing the processes leading to CNV. RPE cells are able to ingest NPs or microparticles in vitro 40, 42, 75 or after in vivo subretinal injection. 43 In vivo, it was reported that PLGA NPs injected into the vitreous of rat eyes followed a 'trans-retinal pathway' and underwent a rapid internalization into the RPE cells layer. 72, 76 In our study, we also observed that most NPs encapsulating the pDNA injected in the vitreous localized within the RPE cells, and the expression of the GFP protein was detected as early as the third day after injection and remained detectable for at least 4 weeks by fluorescence microscope.
Though significant inhibitory efficacy was observed in this study, the possibility that the construction of pDNA was interfered by high-speed stearing exists inevitably. To optimize pDNA-loaded NPs as gene vector, using protamines or arginine during formulation in the future may be benefit for a higher encapsulation efficiency and a greater protection. 77, 78 Taken together, our findings showed that application of HIF-1a-directed shRNA significantly reduced the extent of neovascularization in the murine laser photocoagulation model of CNV. PLGA NPs 'protect' the carried genetic material and obtain a sustained release rate, in addition to offering an increased facility of tissue penetration and intracellular uptake. No deleterious effects on retinal function were observed. Our study provides a novel, non-viral avenue for gene delivery targeting to the posterior segment of the eye such as retina, and especially into the RPE cell layer, though the efficacy of this method is not clear yet and needs further determination. pDNA-loaded PLGA NPs could be a promising candidate for the treatment of human CNV.
Materials and methods
Materials
GFP encoding plasmid (pGCsi. U6.neo.GFP vector) was provided by Shanghai Genechem (Genechem Co Ltd, Shanghai, China). EndoFree Plasmid DNA Extraction kit was obtained from Tiangen Biotech (Tiangen Biotech Co Ltd, Beijing, China). PLGA 50:50 (Mw: 40 000-75 000) and polyvinyl alcohol (Mw: 30 000-70 000) were obtained from Sigma-Aldrich (Sigma Chemical Co, St Louis, MO, USA).
Methods shRNA expressing vector construction. shRNA-expressing sequence driven by U6 promoter was introduced into pGCsi.U6.neo.GFP vector (Figure 8 ) according to the manufacturer's instructions. siRNA target sequence of rat mRNA encoding HIF-1a gene (Genbank No. NM_024359) was as follows: HIF-1a, 5 0 -CCAGTTGAATCTTCAGATA-3 0 . GFP co-expressed plasmid vector produces a shRNA with the loop pDNA-loaded nanoparticles inhibit CNV C Zhang et al sequence: TTCAAGAGA. pGCsi.U6.neo.GFP vector, which produces a non-targeting negative control sequence, was used as the control pDNA throughout the study. Each pDNA was amplified in the DH5a strain of Escherichia coli, purified using an EndoFree Plasmid DNA Extraction kit, and then lyophilized (Virtis Inc., Gardiner, NY, USA).
Preparation of pDNA-loaded PLGA NPs. NPs were prepared by a water-in-oil-in-water (W/O/W) multiple emulsion technique. 42 Briefly, 200 ml of TE buffer (PH ¼ 8.0) containing 200 mg pDNA were emulsified in 2% (w/v) PLGA/methylene chloride solution (2 ml) using a homogenizer (Fluko, Shanghai, China) at 30 000 r.p.m. for 1 min. The resulting primary emulsion was added dropwise into a 12 ml 2% (w/v) polyvinyl alcohol solution (aqueous/organic ¼ 6:1) and homogenized for 4 min to form the double emulsion, then agitated using a magnetic stirrer to remove the organic solvents for 3 h at room temperature. The formed NPs were collected by ultracentrifugation (Xiangyi, Changsha, China) at 25 500 g (4 1C), washed three times with double distilled sterile water, resuspended in double distilled sterile water, and lyophilized to obtain a fine white powder. The unentrapped pDNA was in the supernatant after centrifugation and the loading percent of the NPs was calculated as the following equal formula: loading percent (%) ¼ ((weight of pDNA in supernatant)/(weight of NPs)) Â 100%. Blank NPs were prepared by using TE buffer in the first emulsion.
Particle size and morphology analysis. The average particle size, size distribution and zeta potential of the prepared PLGA NPs were measured by laser light scattering (Zeta Sizer Nano ZS, Malvern Instruments Ltd, Worcestershire, UK). The morphologic characteristics were observed by TEM (JEM-2000E, JEOL Ltd, Tokyo, Japan).
Determination of pDNA content in NPs. A known amount of lyophilized pDNA-loaded NPs (10 mg) were dissolved in 1.0 ml of chloroform and stirred for 20 min.
To this solution, 1.0 ml of water was added and stirred for 20 min. The two phases were separated by centrifugation (20 300 g) for 10 min. The aqueous layer containing the pDNA was removed and used to quantify the encapsulated pDNA by measuring its UV absorption at 260 nm (Ultrospec 2000, Pharmacia Crop., Uppsala, Sweden).
The encapsulation efficiency of the NPs was calculated as the following equal formula: encapsulation efficiency (%) ¼ ((weight of pDNA in NPs)/(weight of pDNA added into emulsion)) Â 100%.
In vitro release. PLGA NPs weighted 20 mg were added to 2.0 ml of 0.02% NaN 3 /PBS (PH ¼ 8.0) solution. The vials were incubated at 37 1C under gentle shaking and samples (0.5 ml) were withdrawn after centrifugation and replaced by the same volume of fresh PBS at regular time intervals. The tests were carried out in triplicate.
Induction of CNV in Brown Norway rats and intravitreal administration. Brown Norway rats (BN, Vitalriver Laboratory, Beijing, China), weighing 200-250 g each, were used in accordance with the Association for Research in Vision and Ophthalmology (ARVO) statement for the use of animals in ophthalmic and vision research. Laser-induced CNV was performed as described earlier. 44 CNV was induced in 112 rats unilaterally. Briefly, the rats were anesthetized for all procedures with an intraperitoneal injection of 1% sodium pentobarbital (45 mg kg À1 ), and the ocular surface was then anesthetized with topical instillation of amethocaine hydrochloride. The pupils were dilated with compound tropicamide/phenylephrine. For each animal, one eye was randomly selected for the laser treatment and eight laser spots (140 mW, 0.1 s, 100 mm) were delivered between the retinal vessels in a peripapillary distribution in each fundus with Nd:YAG laser irradiation (532 nm; Quantel medical, Clermont-Ferrand, France). Production of a subretinal bubble at the time of laser treatment confirmed the rupture of Bruch's membrane. The rats with induced CNV were randomly divided into six groups: PBS-(n ¼ 18), naked pDNA-(non-encapsulated, n ¼ 20), control pDNA NPs-(nontargeting negative control sequence, n ¼ 20), blank NPs-(blank vehicle, n ¼ 14), or pshHIF-1a NPs-injection (as treatment group, n ¼ 18) group and group without intravitreal injection (as control, n ¼ 12). The intravitreal administration was applied immediately after photocoagulation. PBS, blank NPs (1.89 mg ml À1 ), naked pDNA (21.2 mg ml À1 ), control pDNA NPs (1.89 mg ml À1 ) or pshHIF-1a NPs (1.89 mg ml À1 ), in a volume of 10 ml (the pDNA content was equal to 21.2 mg ml À1 ), were injected into the vitreous using a Hamilton microinjector (Hamilton Co., Reno, NV, USA), respectively, according to a previously described method. 43 Eyes with lens injury or vitreous hemorrhage were excluded from the study.
Immunofluorescence. To assess the in vivo kinetics of NPs uptake and their distribution within the eye, 3, 7, 14 and 28 days after photocoagulation, rats were perfused transcardially with 200 ml warm 0.9% saline followed by 400 ml ice cold 4% paraformaldehyde in phosphate buffer (pH ¼ 7.4). Eyes were enucleated and post fixed in the same fixative for 2 h at 4 1C. They were then Figure 8 The map of the vector.
pDNA-loaded nanoparticles inhibit CNV C Zhang et al divided into the anterior and posterior segments and the lens and vitreous were removed form the posterior eye cup, which was cryoprotected subsequently in 30% sucrose in phosphate buffer overnight at 4 1C. Eyes were then embedded in optimal cutting temperature compound medium (OCT, Sakura Finetek Inc., San Diego, CA, USA). Alternate sets of serial vertical sections of the eye were cut at 12 mm thick on a cryostat (CM1900; Leica, Heidelberger, Nussloch, Germany) at À20 1C, dried in the air and rehydrated with PBS; 4 0 , 6-diamidino-2-phenylindole (DAPI, Invitrogen Ltd, Carlsbad, CA, USA) was applied to label the nucleus.
Serial 12 mm-thick frozen sections of rat eyes (12-15 lesions from each group) were chosen for HIF-1a immunofluorescence staining. As notable expression of HIF-1a was detectable since 1 day after laser photocoagulation and peaked at 3 day in pervious research, 52 the specimens at 3 day after laser photocoagulation were chosen for semiquantitative analysis of HIF-1a protein expression. Cryostat sections were dried in the air and rehydrated with PBS, blocked for 2 h in PBS containing 5% bovine serum albumin, 5% normal goat serum, and 1% Triton X-100. Thereafter, slides were incubated overnight at 4 1C in primary antibodies of HIF-1a (1:200; Chemicon International Inc., Temecula, CA, USA). For negative controls, slides were incubated with mouse IgG2b isotype control (1:200; Millipore Co., Billerica, MA, USA) instead of primary antibody or without primary body. After rinsing in PBS, slides were incubated with rhodamine-labeled goat anti-mouse IgG (1:150; Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) and DAPI with three PBS washes in between. Slides were coverslipped and examined with a confocal laser-scanning microscope (FluoView FV-1000, Olympus Inc., Tokyo, Japan). All sections were scanned in multitrack mode to avoid overlap of red (excitation 543 nm), green (excitation 488 nm) and blue (excitation 405 nm) channels. Image-Pro Plus 6.0 software (Media Cybernetics; Silver Spring, MD, USA) was used to measure the images and calculate the data.
Fluorescein fundus angiography. The CNV lesions were studied at 14 day after laser photocoagulation by fluorescein fundus angiography with a digital fundus camera (Heidelberg Retina Angiography; Heidelberg, Germany). 79 Fluorescein sodium with a concentration of 20% (0.5 ml kg
À1
) was injected into the tail vein of the anesthetized rats. Early-phase angiograms were obtained within 1-3 min after injection. For semiquantitative analyses of fluorescein leakage, the area of fluorescein leakage with intensity as high as in major vessles was outlined and calculated as the number of pixels (40 lesions from each group) using Image-Pro Plus software by two specialists who were masked to the treatment of the eyes.
Histopathology of CNV lesions. On day 14 after photocoagulation, the eyes were enucleated and the cornea was punched by a needle to allow for better penetration of the Bouin's fixative (Zhongshan Biotechnologie Co., Beijing, China), and eye cups were made as the foregoing procedure. After routine process of paraffin embedding, serial 4 mm-thick paraffin sections were prepared for staining with hematoxylin and eosin. Eye sections were thoroughly examined, and the CNV with the greatest thickness was selected in each lesion for statistical comparison among the groups and photographed. The distance from the disrupted RPE layer to the top of the lesion was measured using Image-Pro Plus software by a masked pathology technician.
Electroretinography. To further determine whether exposure to NPs was toxic to retinal cells, flash electroretinography (f-ERG) was performed on both eyes of dark-adapted rats (n ¼ 5) in group PBS, blank NPs, naked pDNA, or pshHIF-1a NPs before intravitreal injection (at baseline) and 7, 28 days post injection. ERGs were elicited by flash stimuli delivered by a Ganzfeld photostimulator (VPA-10; Cadwell, Chongqing, China), amplitudes as well as implicit times of a-and b-waves were recorded.
Transmission electron microscopy. For TEM, 4% glutaraldehyde fixed eyes were washed in PBS (pH 7.4) after removal of the cornea and lens, then the equatorial retina of the ablated laser lesions was post fixed with 1% osmium tetroxide, dehydrated in graded ethanol and embedded in agar (Agar Scientific Ltd, Stansted, Essex, UK). Ultra-thin sections were stained with uranylacetate and lead citrate and examined with a transmission electron microscope.
Statistical analysis. All results were expressed as mean ± s.d. Statistical analyses were made using oneway ANOVA by SPSS 11.0 software (SPSS Inc., Chicago, IL, USA). Po0.05 was considered statistically significant. For ERG analyses, Levene's test was used to assess whether the assumption of equal variance across groups was tenable in advance (Po0.10 was considered statistically significant).
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